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Background: Emerging evidence suggests that human cytomegalovirus (HCMV) is highly prevalent in tumours of
different origin. This virus is implied to have oncogenic and oncomodulatory functions, through its ability to control
host gene expression. Human endogenous retroviruses (HERV) are also frequently active in tumours of different
origin, and are supposed to contribute as cofactors to cancer development. Due to the high prevalence of HCMV in
several different tumours, and its ability to control host cell gene expression, we sought to define whether HCMV
may affect HERV transcription.
Findings: Infection of 3 established cancer cell lines, 2 primary glioblastoma cells, endothelial cells from 3 donors
and monocytes from 4 donors with HCMV (strains VR 1814 or TB40/F) induced reverse transcriptase (RT) activity in
all cells tested, but the response varied between donors. Both, gammaretrovirus-related class I elements HERV-T,
HERV-W, HERV-F and ERV-9, and betaretrovirus-related class II elements HML-2 - 4 and HML-7 - 8, as well as
spuma-virus related class III elements of the HERV-L group were up-regulated in response to HCMV infection in
GliNS1 cells. Up-regulation of HERV activity was more pronounced in cells harbouring active HCMV infection, but
was also induced by UV-inactivated virus. The effect was only slightly affected by ganciclovir treatment and was not
controlled by the IE72 or IE86 HCMV genes.
Conclusions: Within this brief report we show that HCMV infection induces HERV transcriptional activity in different
cell types.
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Human cytomegalovirus (HCMV) is a ubiquitous virus
infecting 40-100% of the world’s population. It usually
causes a mild or asymptomatic infection, but may cause
severe and life-threatening disease in immunocom-
promised hosts [1]. Emerging evidence today implies
that HCMV can be detected in very high prevalence in
cancers of different origin e.g. glioblastoma, medullo-
blastoma, neuroblastoma, colon, breast and prostate
cancer [2-10]. It is currently debated whether HCMV is
oncogenic or oncomodulatory in human cancer, although
it fulfills the modified criteria for Koch’s postulates for
human tumour viruses [11,12]. Other viruses implied as
tumour viruses include Epstein Barr virus (EBV), Hepatitis
B and C, human papillomavirus, human herpes virus* Correspondence: cecilia.naucler@ki.se
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reproduction in any medium, provided the or8 (HHV-8), Merkel cell polyomavirus and human
T-lymphotropic virus type 1 (HTLV-1) and recently
human endogenous retroviruses (HERV) [13-15].
HERVs and related retrotransposons constitute ap-
proximately 8% of the human genome [16,17]. Most
HERVs are defective and generally not considered to
be infectious [16,18], but are transmitted vertically.
While they are known to be transcriptionally active
during embryonic development, they are generally
down-regulated in adult human tissues by epigenetic
mechanisms such as DNA methylation or chromatin
modifications [19,20]. However, induction of HERV
transcription is possible under certain circumstances,
and may have a possible role in some pathological
conditions. For example, an increased prevalence of
several HERVs in cancer has led to studies of a poten-
tial role of HERVs in tumour development (reviewed in
[21,22]) and investigation into the idea that HERVs
could be potential therapeutic targets as they representl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the HERV-K(HML-2) group has been detected in high
prevalence in breast and bladder cancer, sarcoma, ma-
lignant melanoma and lymphoma (reviewed in [23]).
This HERV group is considered as the most completeFigure 1 Effects of HCMV on the activity of Mn2+-dependent RT and H
activity in glioma initiating cells GliNS1 (A) and G179NS (B) 5 days post inf
prostate cancer cells PC3 (E) and LNCaP (D); C: RT activity in glioma cell lin
TB40/F; means and standard deviation of 5 independent experiments F: On
representing uninfected and HCMV - infected (VR 1814, MOI 1, 7 dpi) samp
probes has been described previously [26,27] and can be found in the (Ad
HERV loci assigned to one subgroup of multicopy HERV elements with suff
RPL19 and HPRT served as an internal control. Differences between uninfecand biologically most active. Even though not infec-
tious, some proviruses of this group are able to form
retroviral particles, and their gene products could be
pathogenic and might play a role in various human
cancers [22]. For example HERV-K(HML-2) has beenERV transcription profile in human cancer cell lines. A, B: RT
ection with 1 MOI HCMV strain VR 1814 or TB40/F; D, E: RT activity in
e U373 5 days post infection with 1 MOI HCMV strain VR 1814 or
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les. Detailed information about the identity of microarray capture
ditional file 1). Each positive spot on the microarray represents multiple
icient sequence homology. The housekeeping genes upiquitin, GAPD,
ted and infected cells are indicated by red boxes. **p = <0.01.
Figure 2 Effects of HCMV on the activity of Mn2+-dependent RT and HERV transcription profile in cells from healthy donors. A) RT
activity in monocytes from 4 healthy donors (HD1-4) 5 days post infection with 1 MOI HCMV strain VR; B-D: RT activity in HUVEC from 3 healthy
donors (I-III) 1–7 days post infection with 1 MOI HCMV strain VR; means and standard deviation of 2 independent infections in triplicates; E: HERV
transcription profile of uninfected and HCMV infected HUVECs: One representative example of false-colour microarray data sets representing
uninfected and HCMV - infected (VR 1814, MOI 1, 7 dpi) samples. Differences between uninfected and infected cells are indicated by red boxes.
For detailed information see Figure 1 and (Additional file 1). **p = <0.01.
Assinger et al. Retrovirology 2013, 10:132 Page 3 of 7
http://www.retrovirology.com/content/10/1/132
Assinger et al. Retrovirology 2013, 10:132 Page 4 of 7
http://www.retrovirology.com/content/10/1/132implicated in the initiation of malignant transform-
ation and disease progression in melanoma [24,25].
It is widely unclear how HERV gene expression is con-
trolled or induced in pathological processes, including
cancer. Due to the high prevalence of HCMV in different
tumours, and the ability of this virus to control host cell
gene expression, we sought to define whether HCMV
affects HERV expression.
We found that HCMV infection by two different clinical
HCMV isolates, VR1814 and TB40/F, induced HERV
activity in all cancer cell lines tested (for detailed methods
see Additional file 1). Reverse transcriptase activity was
highly induced by both HCMV strains in neural tumour
stem cells, GliNS1 and G179NS, astrocytoma cell line,
U373, and the prostate adenocarcinoma cells LNCaP and
PC3 (Figure 1A-E). HCMV also induced reverse tran-
scriptase activity in human umbilical vein endothelial
cells (HUVEC) and blood-derived monocytes from
healthy individuals, with strong individual variations in
the levels and kinetics of HERV expression between do-
nors (Figure 2A-D). From these data we conclude that
HCMV-induced HERV transcription activity is a general
mechanism that can occur in a variety of cell types, al-
though the exact nature of the response varied.
A RetroArray of HCMV-infected neural tumour stem
cells (GliNS1) revealed that class I gammavirus-related
elements, such as HERV-T, HERV-W, HERV-F and
ERV-9 were up-regulated (Figure 1F). Also class II
betavirus-related elements such as the HERV-K groups
HML-2, -3, -4, -7 and -8 and some class III spuma-virus
related HERV-L groups were expressed at higher levels
in HCMV-infected versus non-infected GliNS1 cells
(Figure 1F). A similar pattern could be observed in
HUVEC from healthy donors, where class I HERV
groups ERV-9 and HERV-F and class II HERV groups
HML-2, -5, and -6 were up-regulated (Figure 2E).
Little is currently known about the induction of
HERV-K(HML-2) expression, although CpG methylation
status of the HERV promoter or their regulatory elements,
have been suggested to be crucial in the regulation of
their activity [28,29]. Interestingly, we recently found
that HCMV causes a general hypomethylation by regulat-
ing DNA methyltransferase (DNMT) 1 and 3 expression
in infected cells [30], which may also affect CpG methyla-
tion of the HML-2 promoter, or their regulatory elements,
and thereby facilitate retroviral activation.
To determine if active HCMV replication is necessary
to induce HERV expression, we tested the effect of UV-
inactivated HCMV and filtered HCMV (0.2 μm pore
size) on reverse transcriptase activity. Inactivated virus
or filtered HCMV supernatant could partly mimic the
effects of HCMV infection on RT activity, but the increase
in HERV transcription activity was far less pronounced
compared to HCMV infection (Figure 3A).We further observed a trend for reduced HCMV-
induced HERV-K(HML-2) transcription (Figure 3C) when
cells were treated with the antiviral agent ganciclovir, im-
plying that early (E) and late (LA) gene products might be
involved in HERV expression and RT-activity. Moreover,
silencing of immediate early (IE) gene products with
siRNA against IE72 and IE86 did not change HCMV-
induced HML-2 transcription (Figure 3D), suggesting
that IE genes were not involved in controlling HERV
transcription in infected cells. Clearly, unidentified soluble
molecules induced by HCMV and present in the inoculum,
as well as during HCMV infection, could induce HML-2
activity. HCMV is dependent on inflammation for its
reactivation, and induces several cytokines and growth
factors [31] that may further enhance HERV activation.
In addition to long terminal repeat (LTR)-containing
HERVs, Long Interspersed Nuclear Element 1 (LINE-1)
may also contribute to the abundant RT activity in human
cancers [32]. LINE-1 elements contain two open reading
frames (ORFs): ORF1 encodes an RNA binding protein,
and ORF2 at least two enzymatic activities, an endonucle-
ase and a reverse transcriptase [33].
To examine whether HCMV not only interferes with
HERV expression, but also modulates LINE-1 activity, we
determined transcription of LINE-1 ORF1 and ORF2 in
response to HCMV infection. While in GliNS1 cells a sig-
nificant increase of HERV-K(HML-2) transcription was
observed 7 days post HCMV infection (Figure 3F), LINE-1
activity peaked at day 5 and was no longer detectable at
day 7 post HCMV infection (Figure 3E). These data indi-
cate that HCMV can also modulate LINE-1 expression and
suggest that HCMV has an impact on various genomic
retroelements. LINE-1 and HERV-K(HML-2) appear to be
influenced by HCMV in different ways, and may both play
functional but distinct roles in the onset and progression
of the tumourigenic process. The lag between LINE-1 and
HERV-K(HML-2) activity could point to an interaction
between these different types of retrotransposons.
Further studies are required to determine if HCMV
causes HERV-K(HML-2) activation in a direct or a LINE-
1 dependent fashion and to evaluate whether HCMV or
HCMV induced HERVs may play a role in tumour devel-
opment or progression. HCMV provides oncomodulatory
functions, and through numerous immune evasion strat-
egies HCMV may lead to tumour development in cells
not undergoing lytic infection. RT inhibiting drugs as well
as LINE-1-specific interference have been shown to dras-
tically reduce the tumourigenic potential of melanoma
cells in vivo [34].
HERVs are suggested to influence tumour development
indirectly e.g. via immunosuppression mediated by the
Env proteins [35] or by expression of regulatory proteins
such as Rec and Np9 that interact with cellular transcrip-
tion factors involved in tumourigenesis [22].
Figure 3 Effects of HCMV replication and IE on HERV-K(HML-2) transcription. A) RT activity in glioma initiating cells GliNS1 (A) 7 days post
infection with 1 MOI HCMV or UV-inactivated HCMV and filtered HCMV (2 μm pore size); (n = 4); B) Effect of GCV on IEcDNA expression induced
by HCMV strain VR 1814 (n = 3) 7 dpi; C) Effect of GCV on HML-2 transcription induced by HCMV strain VR 1814 (n = 3) 7 dpi; D) Effects of siRNA-
IE72 and siRNA-IE86 on VR 1814 induced HML-2 transcription (n = 2). E) Effect of HCMV on LINE-1 expression in GliNS1 at 5 and 7 dpi (n = 3).
F) Effect of HCMV on HML-2 expression in GliNS1 at 5 and 7 dpi (n = 3). Detailed information on the methods are described in the (Additional
file 1). *p = <0.05 **p = <0.01.
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mission, which has so far only been demonstrated
among endogenous animal retroviruses e.g. mouse
leukaemia virus, mouse mammary tumour virus and
porcine endogenous retroviruses (as reviewed in [15]).Therefore, HERVs are currently mainly considered as
possible cofactors in tumour development. Our data
suggests that HCMV and an inflammatory environ-
ment could facilitate HERV activation in vivo in early
tumour lesions.
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presence in certain tumours may present an opportunity
for the development of new therapeutic strategies. Val-
ganciclovir treatment in glioblastoma patients improves
survival [36], and several immunotherapy trials are on-
going to target HCMV in glioblastoma. Furthermore,
similar antigenic determinants are shared between anti-
gen HERV-K-MEL and Bacillus of Calmette Guerin
(BCG), vaccinia as well as yellow fever virus. Therefore
vaccination against these viruses is implied to mediate a
significant, protective effect against HERV positive
melanoma (reviewed in [23]). Thus, both HCMV and
HERVs may be considered as immunological targets for
cancer therapy, while their individual or cooperative
role in cancer needs to be further elucidated.
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Additional file 1: Materials and methods.
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